SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW [1,2,3] -TRIAZOIS PLANNED AS INHIBITORS OF GLYCERALDEIDO-3-PHOSPHATE DEIDROGENASE ENZYME FOR THE TREATMENT OF CHAGAS DISEASEChagas disease, Trypanosoma cruzi, quinolinones, triazoles.
Chagas disease (CD) is an endemic disease discovered in 1909, caused by the protozoan Trypanosoma cruzi, transmitted mainly through vector insects. The CD has had socioeconomic importance due to the ease of locomotion of people with the advent of globalization which has led to the proliferation of the disease. Despite of the many studies in search of trypanocides, there is still no fully effective drug, because although they are trypanocidal, commercially available ones are toxic and have contraindicated side effects. Quinolinones due to their biological diversity are being investigated for treatment of the disease. Therefore, this project proposes the synthetic planning and biological evaluation of new hybrid triazole quinolinones that were planned as bioisosters of substances with trypanocidal activity acting as inhibitors of the enzyme Glyceraldehyde-3-Phosphate Dehydrogenase. Obtaining the series of compounds is based on classical reactions of organic synthesis such as cyclocondensations and diazotization, as well as modern reactions of medical chemistry such as Sonogashira cross coupling and click chemistry reactions. The obtained compounds will be purified and then characterized by spectroscopic techniques (1H and 13C NMR, IR) and MS. In addition to the investigation of the bioactivity profile in vitro models of inhibition of GAPDH and by theoretical methods of molecular modeling of the interaction profile of the series of compounds synthesized with GAPDH, as well as of the correlation structure activity.